Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Study identifier:ACE-LY-002

ClinicalTrials.gov identifier:NCT02112526

EudraCT identifier:2014-001341-25

CTIS identifier:N/A

Recruitment Complete

Official Title

An Open-label, Phase 1b Study of ACP 196 in Subjects with Relapsed or Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Medical condition

Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)

Phase

Phase 1

Healthy volunteers

No

Study drug

Acalabrutinib

Sex

All

Actual Enrollment

21

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 07 Aug 2014
Primary Completion Date: 30 Jun 2020
Estimated Study Completion Date: 01 Apr 2026

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2024 by AcertaPharma

Sponsors

AcertaPharma

Collaborators

-

Inclusion and exclusion criteria